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Abstract 
Objective:  Assess the effect of intensive clinical and educational interventions aimed at reducing risk factors for Cardiovascular 
Disease (CVD), implemented by clinical pharmacists, on modifying risk factors in targeted patients at high risk for CVD. 
Design: Patients with at least two risk factors for CHD were identified at two clinics by conducting a pre-intervention survey and were 
monitored over a period of 6 months with follow up conversations conducted every 4 weeks by phone and at subsequent physician 
visits.  A post-intervention survey was conducted at the end of the study period to detect modified risk factors. 
Setting: The Jefferson County Public Health Department (JCHD) 
Participants: We followed a total of 47 patients over 6 months.  The average age at baseline was 51 years old and 80% of the 
participants were female.  The baseline average number of modifiable cardiovascular disease risk factors was 3.7. 
Measurements: We assessed total number of CVD risk factors, smoking behavior, blood pressure, LDL, A1C, weight, and level of 
physical activity (major modifiable risk factors by the American Heart Association).  
Results: Over a 6 month follow-up of 47 patients, statistically significant reductions occurred in total number of CVD risk factors, 
systolic and diastolic blood pressures, and A1C.  Reductions also occurred in LDL level, weight, and changes in smoking behavior and 
physical activity were identified.  
Conclusions: Results showed that increased patient counseling on adherence and lifestyle changes along with increased disease state 
monitoring and medication adjustment led by a clinical pharmacist can decrease risk factors in patients with multiple risk factors for 
cardiovascular disease. 
  
 
Background 
As Cardiovascular Disease (CVD) continues to be the leading 
cause of mortality in the United States, increasing efforts to 
decrease risk factors for CVD and overall mortality are 
crucial.
1
  Modifiable risk factors for CVD include 
hypercholesterolemia, hypertension, physical inactivity, and 
smoking.  The National Health and Nutrition Examination  
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Survey (NHANES) III data reported that approximately 25% of 
adult Americans are at high risk for cardiovascular disease.
2
  
Intensive research in the area of CVD has shown the positive 
impact of identifying and targeting risk factors for the 
disease.
2-5
  However, realistic and comprehensive ways to 
implement these recommendations have been less than 
forthcoming.  As many clinical pharmacists in ambulatory 
care settings are trained in disease state management and 
medication therapy management, they provide an accessible, 
knowledgeable alternative in providing patient services that 
decrease CVD risk factors.  Previous studies have 
demonstrated that involvement of clinical pharmacists in 
integrated patient care models can decrease CVD risk factors 
and improve outcomes.
6-10
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The Jefferson County Department of Health (JCDH), located in 
Birmingham, AL, presents an excellent opportunity to 
implement CVD risk factor modifying techniques due to the 
high rates of CVD in the patient population as well as its 
integrated healthcare team approach.  With over 300 deaths 
per 100,000 citizens in 2011, the state of Alabama ranks 
second among all US states and provinces in rates of CVD.
1
  
The following prospective clinical trial was conducted at JCDH 
to evaluate the outcomes of pharmacist-implemented clinical 
interventions in decreasing risk factors for cardiovascular 
disease in patients with two or more risk factors for CVD.  The 
primary outcome being studied was a decrease in total 
number of CVD risk factors.  Secondary outcomes include 
change in LDL leve, A1c level, smoking status, physical activity, 
weight, and systolic and diastolic blood pressure. 
 
Methods 
After obtaining IRB approval from Samford University and 
JCDH, patients with at least two risk factors for CVD were 
identified at two JCDH clinics by conducting a pre-
intervention survey.   Upon providing written consent, 
patients agreed to be monitored over a period of six months 
with follow-up conversations conducted every four weeks by 
phone and at subsequent physician visits.   
 
Inclusion criteria for the study included patients greater than 
20 years of age, current patient at JCDH, greater than or 
equal to two risk factors for CVD, and one visit with a primary 
care physician in the past year.  Exclusion criteria for the 
study included less than 20 or greater than 80 years of age, 
not a current patient at JCDH, and non-English speaking 
patients.   
 
A total of 47 patients were enrolled into the study.  Out of 47 
patients, 16 were active smokers, 23 had uncontrolled 
hypertension, 17 had uncontrolled hyperlipidemia, 26 had 
uncontrolled diabetes mellitus, 46 were obese, and 40 were 
self-reportedly physically inactive.  The average number of 
CVD risk factors was 3.7 and the average Framingham score 
was 4.6.  The average age of enrolled patients was 51 years 
old and 80% of patients were female.  See Table 1 for a 
review of baseline risk factors and patient characteristics.  
 
Clinical interventions including medication adjustment and/or 
initiation, patient education and counseling, and support in 
accessing pharmacologic therapy through medication 
assistance programs were implemented based on patient-
specific risk factors.  CVD risk factors assessed included: 
smoking, hypertension (measured by systolic and diastolic 
blood pressures), hyperlipidemia (measured by calculated 
LDL level), obesity (measured by weight and BMI), physical 
inactivity and diabetes (measured by A1c).  The following risk 
factor-specific interventions were made over the course of six 
months.  Every patient with a positive smoking status was 
counseled by a pharmacist in the JCDH smoking cessation 
clinic.  Eligible positive smoking status patients also received 
Nicotine Replacement Therapy (NRT) through the Alabama 
Tobacco Quitline and/or varenicline through the Pfizer 
Patient Assistance Program®.  All patients with diabetes and 
patients with uncontrolled dyslipidemia and/or hypertension 
were counseled by a pharmacist on lifestyle modifications.  
Pharmacist-directed disease state-specific medication 
adjustments were made in 70% of diabetic patients , 23% of 
dyslipidemia patients, and 60% of hypertensive patients 
followed.  All patients with obesity and/or physical inactivity 
were counseled by a pharmacist on weight loss, exercise, and 
lifestyle modifications. 
 
Patients were followed by clinical pharmacists through either 
appointments in the pharmacist run Diabetes Clinic, 
pharmacist run Smoking Cessation Clinic, primary care 
physician visits, or telehealth visits. During follow-up 
conversations, patients were assessed based on change in 
smoking status, physical activity, systolic and diastolic blood 
pressure, current lipid panel, fasting plasma glucose levels, 
A1c levels, weight, and Body Mass Index (BMI).  Initially, 
current aspirin therapy was assessed, but was not evaluated 
for the six month period.  Clinical pharmacists educated 
patients during these conversations and ascertained the need 
for any adjustments in medication therapy.  
Recommendations for medication adjustments were 
communicated to the patient’s primary care physician at 
JCDH for implementation.  
 
A post-intervention survey was conducted at the end of the 
study period by either telephone or primary care visit to 
detect the number and degree of change in CVD risk factors.  
A risk factor was considered at goal if it met the following 
criteria: smoking cessation, a blood pressure of less than 
140/90 mmHg or less than 130/80 mmHg in patients with 
diabetes and/or chronic kidney disease, an LDL below 100 
mg/dL, a BMI below 25 kg/m², an A1c below 7%, and physical 
activity of at least 30 minutes per day, most days of the week.   
An intervention was considered successful if at least one risk 
factor was modified.  Data management and analysis was 
conducted using Microsoft EXCEL® and Minitab 16.2.2. 
 
Results 
Over the course of six months, communication was 
maintained at least every four weeks with all 47 patients 
initially enrolled.  Overall, statistically significant decreases 
were seen in total number of CVD risk factors, systolic blood 
pressure, diastolic blood pressure, and A1c.  There were no 
statistically significant changes in LDL, weight, BMI, smoking 
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behavior, or physical activity (Table 2).  The primary outcome 
being studied, number of total CVD risk factors significantly 
decreased from 3.74± at baseline to 3.06± (0.49, 0.87, 
p<0.001) post-intervention.  Notably, at baseline four 
patients (8%) had all six CVD risk factors targeted, ten 
patients (20%) had five, and ten patients (20%) had four. 
Following intervention, only one patient (2%) still had all six 
CVD risk factors, five (10%) had five risk factors, and nine 
(19%) had four risk factors.   
 
Mean systolic blood pressure (SBP) post-intervention was 
126.72±18.49 mmHg compared to baseline SBP of 
134.92±21.58 mmHg. This represented a difference of 
8.2±6.1 mmHg (2.11, 14.28, p = 0.009).  Similarly, diastolic 
blood pressure (DBP) averaged 80.34±9.63 mmHg post-
intervention compared to 86.85±12.35 mmHg at baseline.  
Change in DBP was calculated as 6.51±2.9 mmHg (3.63, 9.39, 
p<0.001).  Average A1c was decreased from 9.44±2.19% to 
8.49±1.67% (0.37, 1.53, p=0.002). 
 
Out of ten baseline smokers, seven decreased smoking 
frequency and two patients stopped smoking altogether.  At 
baseline, 41 patients reported that they were physically 
inactive.  After clinical pharmacist intervention, only 4 
patients reported having less than 30 minutes per day most 
days of the week of physical activity. 
   
Discussion 
We found that interventions implemented by clinical 
pharmacists at JCDH significantly decreased total number of 
patient risk factors for cardiovascular disease in patients with 
two or more baseline risk factors.  Major risk factors that 
were modified include systolic and diastolic blood pressures 
and A1c.  Medication adjustment occurred in 70% of diabetic 
patients and 60% of uncontrolled hypertensive patients.  
These adjustments were made based on the pharmacists’ 
assessment of outcomes on current therapy.  While blood 
pressure can respond promptly to medication changes, a 
significant change in A1c level over six months is less quickly 
achieved.  This change was most likely a result of intensive 
counseling along with oral and insulin medication 
adjustments. 
 
Risk factors that were not modified during the course of this 
study include obesity, physical inactivity, smoking behavior, 
and LDL levels.  One possible reason for the lack of change in 
obesity and physical inactivity is that they are less easily 
targeted by medication adjustment.  While structured 
counseling was provided on dietary and lifestyle changes, no 
medication was initiated to modify these risk factors.  
Varenicline was provided to 38% of active smokers enrolled.  
Varenicline is currently the only FDA approved partial 
nicotine agonist and may take up to 12 weeks of compliant 
administration for positive outcomes to occur.  However, 
many patients are unable to complete the full course due to 
side effects such as abnormal dreams, headache, and 
insomnia.  Similar to A1c levels, LDL levels can take an 
extended period of time in which to see reductions.
11
  
Medication adjustment only occurred in 25% of patients with 
uncontrolled dyslipidemia.  The low percentage of changes 
could have resulted from the average LDL level at baseline 
being within the ATPIII goal of <100 mg/dL in diabetic 
patients at 96.96 mg/dL.  Patients who met this goal were 
less likely to be initiated on or have changes in hyperlipidemia 
medication therapy. 
 
All patients enrolled in the study received written and oral 
education on their baseline risk factors and improving these 
through lifestyle modifications.  Patient education provided 
by clinical pharmacists was thorough, comprehensible, and 
structured.  Clinical pharmacists monitored patients for 
medication adjustments to improve current therapy.  From 
the success of this study, it can reasonably be concluded that 
frequent follow-up and communication with high risk 
patients improves outcomes by decreasing CVD risk factors.  
While studies have shown the correlation between increased 
monitoring of risk factors and improved outcomes, this study 
uniquely demonstrates that the clinical pharmacist can be 
integral and advantageous when implementing such 
interventions.
6-10
  Recently the U.S. Surgeon General, Dr. 
Regina Benjamin, outlined that “health leaders and policy 
makers need to support evidence-based models of cost 
effective patient care that utilizes the expertise and 
contributions of our nation’s pharmacists as an essential part 
of the healthcare team.”  Clinical pharmacists are trained as 
medication experts and are in an optimal position to lead 
such interventions as those implemented in this study in 
ambulatory care settings.   
 
Limitations to this study included the short study duration of 
only six months, lack of comparator group which limits the 
study’s ability to attribute outcomes solely to pharmacist’s 
interventions, and self-reported estimates of smoking status 
and frequency and duration of exercise. 
 
Conclusion 
Statistically significant results showed that increased patient 
counseling on adherence and lifestyle changes along with 
increased disease state monitoring and medication 
adjustment led by a clinical pharmacist can decrease risk 
factors in patients with multiple risk factors for cardiovascular 
disease.  Clinical pharmacists are in an optimal position to 
provide effective interventions aimed at decreasing risk 
factors for cardiovascular disease.  Increased monitoring for 
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cardiovascular disease presence and progression is 
recommended in both symptomatic and asymptomatic 
adults.
2
  Further research and consideration into the role of 
the clinical pharmacists in implementing interventions 
targeted at decreasing risk factors for cardiovascular disease 
is warranted. 
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Table 1: Baseline Characteristics 
 
Characteristic Average at Baseline 
Age (years) 51 
Female (%) 80 
Average Framingham Risk Score 4.6 
Average number of  
CVD Risk Factors 
3.7 
Smoker 16 
Blood Pressure (mmHg) 135/87 
LDL (mg/dL) 97 
A1c (%) 9.4 
Weight (kg) 95 
BMI (kg/m
2
) 34 
Physical Inactivity (%) 85 
 
 
 
Table 2: Risk Factor Assessment 
 
Characteristic 
Average at 
Baseline 
Average at Study 
Completion 
Mean Difference 
P-Value 
95% Confidence 
Interval 
Total number of 
CVD Risk Factors 
3.7 3.1 
0.68 <0.001 0.49, 0.87 
Systolic Blood Pressure (mmHg) 135 126 
8.19 0.009 2.1, 14.28 
Diastolic Blood Pressure (mmHg) 86.9 80.3 
6.51 <0.001 3.63. 9.39 
A1c (%) 9.4 8.5 
0.95 0.002 0.37, 1.53 
Weight (kg) 210 208 
1.79 0.089 -0.28, 3.87 
BMI (kg/m
2
) 34 34 
0.21 0.346 -0.23, 0.66 
LDL (mg/dL) 97 94 
2.65 0.283 -2.72, 7.58 
 
 
